Bank of America’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$287K Sell
60,100
-13,759
-19% -$75.5K ﹤0.01% 5178
2025
Q4
$399K Buy
73,859
+43,796
+146% +$199K ﹤0.01% 5034
2025
Q3
$147K Sell
30,063
-1,234
-4% -$6.54K ﹤0.01% 6421
2025
Q2
$147K Buy
31,297
+7,462
+31% +$31.2K ﹤0.01% 6327
2025
Q1
$87K Sell
23,835
-7,827
-25% -$35.7K ﹤0.01% 6550
2024
Q4
$149K Buy
31,662
+4,002
+14% +$29.2K ﹤0.01% 6236
2024
Q3
$258K Buy
27,660
+753
+3% +$5.45K ﹤0.01% 5884
2024
Q2
$155K Buy
26,907
+14,179
+111% +$84.5K ﹤0.01% 6029
2024
Q1
$85.4K Sell
12,728
-16,345
-56% -$90.7K ﹤0.01% 6317
2023
Q4
$188K Buy
29,073
+15,375
+112% +$66.3K ﹤0.01% 6102
2023
Q3
$68.5K Buy
13,698
+6,175
+82% +$47.6K ﹤0.01% 6396
2023
Q2
$53K Sell
7,523
-887
-11% -$6.2K ﹤0.01% 6444
2023
Q1
$52.1K Sell
8,410
-5,779
-41% -$37.8K ﹤0.01% 6491
2022
Q4
$90.5K Buy
14,189
+5,116
+56% +$38.6K ﹤0.01% 6266
2022
Q3
$78K Sell
9,073
-2,163
-19% -$27.8K ﹤0.01% 6465
2022
Q2
$153K Sell
11,236
-3,792
-25% -$48.9K ﹤0.01% 6265
2022
Q1
$229K Sell
15,028
-4,985
-25% -$68.4K ﹤0.01% 6391
2021
Q4
$458K Buy
20,013
+8,033
+67% +$115K ﹤0.01% 5951
2021
Q3
$167K Sell
11,980
-290
-2% -$3.21K ﹤0.01% 6422
2021
Q2
$131K Buy
12,270
+6,861
+127% +$74.8K ﹤0.01% 6357
2021
Q1
$71K Buy
5,409
+3,755
+227% +$61.5K ﹤0.01% 6514
2020
Q4
$34K Buy
+1,654
New +$31.7K ﹤0.01% 6455

Other funds holding FHTX

Bank of America's FHTX Position: Q1 2026 in Review

Bank of America reduced its Foghorn Therapeutics (FHTX) stake by 19% in Q1 2026, selling an estimated $75.5K and leaving 60,100 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #5178.

Bank of America first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $458K in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Bank of America held 60,100 shares of Foghorn Therapeutics worth $287K as of Q1 2026.
  • Bank of America sold 13,759 Foghorn Therapeutics shares in Q1 2026, an estimated $75.5K.
  • Foghorn Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5178 holding.
  • Bank of America first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Bank of America's Foghorn Therapeutics position peaked at $458K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.